share_log

和黄医药(00013.HK):在中国启动HMPL-306治疗伴有IDH1及/或IDH2突变的复发/难治性急性髓系白血病患者的RAPHAEL注册性III期研究

Hehuang Pharmaceutical (00013.HK): Initiating a RAPHAEL registered phase III study on HMPL-306 in the treatment of relapsed/refractory acute myeloid leukemia patients with IDH1 and/or IDH2 mutations in China

Gelonghui Finance ·  May 13 20:16

On May 14, Ge Longhui Pharmaceutical (00013.HK) announced today the launch of a registered phase clinical trial of HMPL-306 to treat relapsed/refractory acute myeloid leukemia (AML) with isocitrate dehydrogenase (“IDH”) 1 or 2 mutations in China. The first test subject received the first dose of medication on May 11, 2024.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment